Wall Street Realizes Myriad Genetics, Inc. (MYGN) Monopoly on Breast Cancer Risk Tests is Done
6/14/2013 6:47:42 AM
More...
|
Myriad Genetics, Inc. (MYGN) to Present at the Goldman, Sachs & Co. Global Healthcare Conference
6/3/2013 10:24:48 AM
More...
|
AstraZeneca PLC (AZN) Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis®
6/3/2013 10:22:15 AM
More...
|
Myriad Genetics, Inc. (MYGN) to Present PROLARIS® Data at American Society of Clinical Oncology 2013, Continuing Its Commitment to Cancer Research
5/30/2013 9:53:30 AM
More...
|
Angelia Jolie Surgery Pushes Myriad Genetics, Inc. (MYGN) Into Spotlight
5/15/2013 7:49:13 AM
More...
|
Myriad Genetics, Inc. (MYGN) to Present at the Bank of America (BAC) Merrill LynchHealth Care Conference
5/14/2013 9:12:11 AM
More...
|
Myriad Genetics, Inc. (MYGN) Announces 2013 Analyst and Investor Day
5/3/2013 10:22:33 AM
More...
|
BioPharm Executive: Myriad Genetics, Inc. (MYGN), Glivec, and the $1 Billion "Myth"
4/22/2013 2:52:33 PM
More...
|
Myriad Genetics, Inc. (MYGN) to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013
4/19/2013 11:17:48 AM
More...
|
Myriad Genetics, Inc. (MYGN) Partners With PharmaMar S.A. for New HRD Test
3/29/2013 8:23:55 AM
More...
|
|